Targeting cell cycle regulators in hematologic malignancies
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Hematologic malignancies represent the fourth most frequently diagnosed cancer in economically developed countries. In hematologic malignancies normal hematopoiesis is interrupted by uncontrolled growth of a genetically altered stem or progenitor cell (HSPC) that maintains its ability of self-renewal. Cyclin-dependent kinases (CDKs) not only regulate the mammalian cell cycle, but also influence other vital cellular processes, such as stem cell renewal, differentiation, transcription, epigenetic regulation, apoptosis, and DNA repair. Chromosomal translocations, amplification, overexpression and altered CDK activities have been described in different types of human cancer, which have made them attractive targets for pharmacological inhibition. Mouse models deficient for one or more CDKs have significantly contributed to our current understanding of the physiological functions of CDKs, as well as their roles in human cancer. The present review focuses on selected cell cycle kinases with recent emerging key functions in hematopoiesis and in hematopoietic malignancies, such as CDK6 and its role in MLL-rearranged leukemia and acute lymphocytic leukemia, CDK1 and its regulator WEE-1 in acute myeloid leukemia (AML), and cyclin C/CDK8/CDK19 complexes in T-cell acute lymphocytic leukemia. The knowledge gained from gene knockout experiments in mice of these kinases is also summarized. An overview of compounds targeting these kinases, which are currently in clinical development in various solid tumors and hematopoietic malignances, is presented. These include the CDK4/CDK6 inhibitors (palbociclib, LEE011, LY2835219), pan-CDK inhibitors that target CDK1 (dinaciclib, flavopiridol, AT7519, TG02, P276-00, terampeprocol and RGB 286638) as well as the WEE-1 kinase inhibitor, MK-1775. The advantage of combination therapy of cell cycle inhibitors with conventional chemotherapeutic agents used in the treatment of AML, such as cytarabine, is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 3×
“The activity of CDK/cyclin complexes is frequently perturbed in human cancer (Lapenna and Giordano, 2009; Malumbres and Barbacid, 2009).”
BackgroundClonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Wilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.048 · Cited by 1,908
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378 · cited 1×
“Patients with chronic myeloid leukemia (CML) carry the BCR/ABL fusion protein (De Klein et al., 1982; Shtivelman et al., 1985).”
BackgroundFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 11×
“LEE011 (Novartis) is an orally bioavailable small molecule that inhibits CDK4/6 at nanomolar concentrations (Gelbert et al., 2011; Kim et al., 2013).”
BackgroundInfluentialATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells
Cheshier, S. H., Morrison, S. J., Liao, X., & Weissman, I. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3120 · Cited by 858 · cited 2×
“The HSC population is relatively quiescent (Bradford et al., 1997; Cheshier et al., 1999), but upon cell cycle entry it will give rise to differentiating progenitor populations that undergo massive proliferative expansion in order to replenish the blood system on a daily basis but also in response…”
BackgroundDeconstructing stem cell self-renewal: genetic insights into cell-cycle regulation
Orford, K. W., & Scadden, D. T. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2269 · Cited by 851 · cited 2×
“Quiescence is thought to prevent stem cell exhaustion (Orford and Scadden, 2008) and to help protect stem cells from acquiring mutations leading to their malignant transformation (Park and Gerson, 2005; Wang and Dick, 2005; Lobo et al., 2007).”
BackgroundInfluentialMammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · cited 2×
“…lactotrophs in mice (Rane et al., 1999; Tsutsui et al., 1999; Moons et al., 2002; Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 April 2015 | Volume 3 | Article 16 Martin et al., 2003; Jirawatnotai et al., 2004), CDK6 has a unique role in hematopoiesis (Malumbres et al., 2004).”
BackgroundDiehl, J. A., Zindy, F., & Sherr, C. J. (1997) · Genes & Development · doi:10.1101/gad.11.8.957 · Cited by 746 · cited 2×
“…D1b, that forms an active complex with CDK4, (Lu et al., 2003; Solomon et al., 2003) but it lacks the residue necessary for nuclear export and subsequent cytoplasmic degradation (Diehl et al., 1997), thereby stabilizing cyclin D1 protein and increasing its oncogenic potential (Alt et al., 2000).”
BackgroundNuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways
Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.035 · Cited by 719
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700 · cited 1×
“While CDK4 is required by the pancreatic beta cells and pituitary lactotrophs in mice (Rane et al., 1999; Tsutsui et al., 1999; Moons et al., 2002; Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 April 2015 | Volume 3 | Article 16 Martin et al., 2003; Jirawatnotai et al., 2004),…”
BackgroundPassegué, E., Wagers, A. J., Giuriato, S., Anderson, W. C., & Weissman, I. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050967 · Cited by 646
Disruption of differentiation in human cancer: AML shows the way
Tenen, D. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc989 · Cited by 612 · cited 2×
“Pharmacological inhibitors of CDK4/6 have been developed and are currently being tested in clinical trials (Supplementary Table 3).”
BackgroundAlt, J. R., Cleveland, J. L., Hannink, M., & Diehl, J. A. (2000) · Genes & Development · doi:10.1101/gad.854900 · Cited by 535
Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522 · cited 1×
“CDK12 and CDK13 in complex with cyclin K control RNA pol II transcription (Bartkowiak et al., 2010; Blazek et al., 2011; Cheng et al., 2012), and CDK12/cyclin K controls DNA damage response (Blazek et al., 2011).”
BackgroundIDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513 · cited 3×
“Dinaciclib (SCH 727965, Merck) is a pyrazolo [1,5-α]pyrimidine that potently inhibits CDK1, CDK2, CDK5, and CDK9 (Parry et al., 2010; Paruch et al., 2010) with IC50 values ranging from 1 to 4 nM in a broad spectrum of human cancer cell lines including MCL, NHL, leukemia, colon, pancreatic, breast,…”
BackgroundChromosome translocations in multiple myeloma
Bergsagel, P. L., & Kuehl, W. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204641 · Cited by 478
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Growney, J. D., Shigematsu, H., Li, Z., Lee, B. H., Adelsperger, J., Rowan, R., Curley, D. P., Kutok, J. L., Akashi, K., Williams, I. R., et al. (2005) · Blood · doi:10.1182/blood-2004-08-3280 · Cited by 462
Cell cycle regulation in hematopoietic stem cells
Pietras, E. M., Warr, M. R., & Passegué, E. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102131 · Cited by 447
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429 · cited 2×
“Interestingly, in mouse models the kinase activities of some cyclin/CDK complexes, such as CDK4 and CDK2, appear dispensable for normal mouse development, but are required for mammary tumor development (Yu et al., 2006; Ray et al., 2011).”
BackgroundTargeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27 Kip1 Activity
Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., & Kiyokawa, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7011 · Cited by 395
Diril, M. K., Ratnacaram, C. K., Padmakumar, V. C., Du, T., Wasser, M., Coppola, V., Tessarollo, L., & Kaldis, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115201109 · Cited by 385 · cited 2×
“Pharmacological inhibitors of CDK4/6 have been developed and are currently being tested in clinical trials (Supplementary Table 3).”
BackgroundFlaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342 · cited 2×
“Mitosis starts after WEE-1 is degraded and CDC25C phosphatase releases the inhibitory phosphorylation on CDK1/cyclin B.”
BackgroundScaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337 · cited 2×
“However, its inhibition significantly reduced tumor growth of trastuzumab-resistant xenografts from patients with Her+/amplified cyclin E breast cancer (Scaltriti et al., 2011).”
BackgroundCyclins D2 and D1 Are Essential for Postnatal Pancreatic β-Cell Growth
Kushner, J. A., Ciemerych, M. A., Sicinska, E., Wartschow, L. M., Teta, M., Long, S. Y., Sicinski, P., & White, M. F. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3752-3762.2005 · Cited by 334 · cited 1×
“Mice lacking cyclin D2 show impaired proliferation of B-lymphocytes (Kushner et al., 2005) and cyclin D3−/− mice display hypoplastic thymuses and are resistant to Notch-driven leukemia (Sicinska et al., 2003).”
BackgroundA Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313 · cited 4×
“CDK6 binds the promoters of p16INK4a and VEGF-A through interaction with the transcription factors STAT-3 and c-Jun (Kollmann et al., 2013).”
BackgroundInfluentialSelective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299 · cited 2×
“Five patients achieved progression-free survival (PFS) of greater than a year, with 1 complete (CR) and 2 partial responses (PRs) (18% objective response rate) (Leonard et al., 2012).”
BackgroundMizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298 · cited 1×
“…FLT3 contribute to the development of AML as they cause self-phosphorylation and ligand-independent activation of the FLT3 receptor and downstream signaling pathways such as STAT3, STAT5, ERK1/2, and AKT (Hayakawa et al., 2000; Mizuki et al., 2000, 2003; Tse et al., 2000; Spiekermann et al., 2003).”
BackgroundNuchprayoon, I., Meyers, S., Scott, L. M., Suzow, J., Hiebert, S., & Friedman, A. D. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5558 · Cited by 296
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
The cyclin-dependent kinase 8 module sterically blocks Mediator interactions with RNA polymerase II
Elmlund, H., Baraznenok, V., Lindahl, M., Samuelsen, C. O., Koeck, P. J. B., Holmberg, S., Hebert, H., & Gustafsson, C. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607483103 · Cited by 230 · cited 1×
“This phosphorylation disrupts EZH2 binding with the other PRC2 components SUZ12 and EED, and inhibits EZH2 methyltransferase activity, resulting in inhibition of cancer-cell invasion as well (Wei et al., 2011).”
BackgroundBaughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225 · cited 14×
“One trial is in MM, another Phase II study includes patients with MCL and the remaining studies are in solid tumors (clinicaltrials.gov, accessed 11/2014) (Supplementary Table 4).”
BackgroundInfluentialZhang, D.-E., Fujioka, K.-I., Hetherington, C. J., Shapiro, L. H., Chen, H.-M., Look, A. T., & Tenen, D. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8085-8095.1994 · Cited by 199 · cited 2×
“It regulates lineage-specific genes and it directly stimulates G1 to S cell cycle progression (Redondo et al., 1992; Nuchprayoon et al., 1994; Zhang et al., 1994; Elagib et al., 2003).”
BackgroundTherapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170 · cited 8×
“In MLL-rearranged leukemia, PD0332991 strongly inhibits colony formation in methylcellulose of MLL-AF9 positive AML cell lines and of mononuclear cells from patient derived AML samples (Placke et al., 2014).”
BackgroundInfluentialNotch activation inhibits AML growth and survival: a potential therapeutic approach
Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., Akers, L. J., Hammitt, R. A., McMurray, J. S., Kornblau, S. M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121527 · Cited by 152 · cited 1×
“This phosphorylation disrupts EZH2 binding with the other PRC2 components SUZ12 and EED, and inhibits EZH2 methyltransferase activity, resulting in inhibition of cancer-cell invasion as well (Wei et al., 2011).”
BackgroundWang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134 · cited 5×
“Inhibition of FLT3-ITD in AML leads to down regulation of cyclin D2 and D3, both activators of CDK6 (Wang et al., 2007), which suggests that CDK6 may be an additional candidate for therapeutic targeting in FLT3-ITD-driven AML.”
BackgroundInfluentialCheng, S.-W. G., Kuzyk, M. A., Moradian, A., Ichu, T.-A., Chang, V. C.-D., Tien, J. F., Vollett, S. E., Griffith, M., Marra, M. A., & Morin, G. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06267-11 · Cited by 124
Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα
Radomska, H. S., Alberich-Jordà, M., Will, B., Gonzalez, D., Delwel, R., & Tenen, D. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci43354 · Cited by 67
Suppression of Mediator is regulated by Cdk8-dependent Grr1 turnover of the Med3 coactivator
Gonzalez, D., Hamidi, N., Del Sol, R., Benschop, J. J., Nancy, T., Li, C., Francis, L., Tzouros, M., Krijgsveld, J., Holstege, F. C. P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307525111 · Cited by 43 · cited 2×
“Mitosis is initiated by CDK1/cyclin B complex.”
BackgroundInfante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-a276 · Cited by 16
Cited by
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
Maier, P., Hartmann, L., Wenz, F., & Herskind, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010102 · Cited by 414
T-cell acute lymphoblastic leukemia
Raetz, E. A., & Teachey, D. T. (2016) · Hematology · doi:10.1182/asheducation-2016.1.580 · Cited by 317
Structural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Metadata
- Authors
- Aleem, E., & Arceci, R. J.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2015-04-09
- Volume
- 3
- Pages
- 16-16
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W1979491540
- Cited by
- 120
- References
- 48
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.